Table 2.
Prior Single-Institution Studies of Adjuvant RT for ACC
| Study | Year | No. of Cases | Radiation Dose (Gy) | Chemotherapy or Mitotane, n (%) | Local Control, n (%) |
|---|---|---|---|---|---|
| Percarpio (26) | 1976 | 4 | 28–40 | NR | 1/4 (25) |
| Henley (27) | 1983 | 10 | NR | NR | 1/10 (10) |
| Markoe (28) | 1991 | 5 | 42–60 | 2/5 (40) | 3/5 (60) |
| Pommier (29) | 1992 | 3 | 39–45 | NR | 0/3 (0) |
| Fassnacht (7) | 2006 | 14 | 40-54 | 5/14 (36) | 12/14 (86) |
| Hermsen (30) | 2010 | 3 | NR | NR | 3/3 (100) |
| Habra (8) | 2013 | 16 | 36–59.4 | 4/16 (25) | 9/16 (56) |
| Sabolch (9) | 2015 | 20 | 45–60 | 15/20 (75) | 19/20 (95) |
| Atallah (31) | 2017 | 6 | NR | 2/6 (33) | 5/6 (83) |
| Srougi (16) | 2017 | 10 | 45–54 | NR | 6/10 (60) |
| Gharzai | Present study | 39 | 45–60 | 30/39 (77) | 26/39 (67) |
Abbreviation: NR, not reported.